Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Gene therapy strategies for the treatment of inherited retinal diseases have made major advances in recent years. This review focuses on adeno-associated viral (AAV) vector approaches to treat retinal degeneration and, thus, prevent or delay the onset of blindness. Data from human clinical trials of gene therapy for retinal disease show encouraging signs of safety and efficacy from AAV vectors. Recent progress in enhancing cell-specific targeting and transduction efficiency of the various retinal layers plus the use of AAV-delivered growth factors to augment the therapeutic effect and limit cell death suggest even greater success in future human trials is possible.

Original publication

DOI

10.1016/j.trsl.2012.12.007

Type

Journal article

Journal

Transl Res

Publication Date

04/2013

Volume

161

Pages

241 - 254

Keywords

Animals, Clinical Trials as Topic, Genetic Therapy, Genetic Vectors, Humans, Neuroprotective Agents, Promoter Regions, Genetic, Retinal Diseases